Details:
NanaBis™ (tetrahydrocannabinol) is an investigative novel analgesic for cancer patients comprising equal parts of CBD and THC encapsulated in Medlab’s patented delivery platform, NanoCelle®. NanaBis™ is applied to the oro-buccal membrane for rapid uptake.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: NanaBis
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
Phase 3 trial of its allogeneic cell therapy MPC-06-ID ( rexlemestrocel-L), showed a durable reduction in back pain lasting at least three years from a single intra-discal injection in patients with chronic low back pain (CLBP) associated with degenerative disc disease.
Lead Product(s): Rexlemestrocel-L,Hyaluronic Acid
Therapeutic Area: Neurology Product Name: MPC-06-ID
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
A key objective of MPC-06-ID (rexlemestrocel-L) is to demonstrate reduction in pain and opioid usage and and position rexlemestrocel-L as a potential opioid-sparing agent.
Lead Product(s): Rexlemestrocel-L,Hyaluronic Acid
Therapeutic Area: Neurology Product Name: MPC-06-ID
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
A single injection of rexlemestrocel-L may provide a durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease. Greatest benefits were seen when administered earlier in the disease process.
Lead Product(s): Rexlemestrocel-L,Hyaluronic Acid
Therapeutic Area: Neurology Product Name: MPC-06-ID
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021